Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem

Published:2021-11-15 Issue:12 Volume:21 Page:1333-1353
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Gatto Lidia¹,Franceschi Enrico²^ORCID,Di Nunno Vincenzo¹^ORCID,Maggio Ilaria¹,Lodi Raffaele³⁴,Brandes Alba Ariela²^ORCID

Affiliation:

1. Medical Oncology Department, Azienda USL, Bologna, Italy

2. IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Oncologia Medica del Sistema Nervoso, Bologna, Italy

3. IrcssIstituto di Scienze Neurologiche di Bologna, Bologna, Italy

4. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1997599

Reference222 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences

3. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

4. Lomustine and Bevacizumab in Progressive Glioblastoma

5. Mechanisms of immunotherapy resistance: lessons from glioblastoma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of cancer stem cells and immunotherapy of glioblastoma (Review);Biomedical Reports;2023-12-19

2. Spinal ependymoma in adults: from molecular advances to new treatment perspectives;Frontiers in Oncology;2023-11-24

3. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap;Frontiers in Oncology;2023-06-16

4. Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022;Expert Opinion on Drug Discovery;2023-02-16

5. Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?;Cancers;2023-02-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3